Coronavirus (COVID-19): visiting The Royal Marsden suspended

Coronavirus (COVID-19) latest: Visiting The Royal Marsden is still suspended, but we want to reassure our patients, their families and anyone worried about cancer during this difficult time that we are still delivering treatment - the hospital is open. Please see more information here about how we are keeping everyone safe.

Dr Susan Lalondrelle

Consultant Clinical Oncologist, Lead for Clinical Oncology, Honorary Faculty ICR MD FRCR MRCP BM BSc

Specialism: Gynaecology, Radiotherapy, Skin

Available at: Chelsea, Sutton

Special interests:

Gynaecology:

  • Advanced radiotherapy techniques for gynaecological cancers : MRguided RT, stereotactic RT, brachytherapy, IGRT, VMAT/IMRT
  • Systemic therapy including immunotherapy for cervical, endometrial and vulval cancer

Skin:

  • Superficial and electron therapy for non-melanoma skin cancer
  • Brachytherapy for skin tumours 
  • Systemic therapy including immunotherapy for non-melanoma skin cancers

​Biography

Dr Lalondrelle has both a private and an NHS practice at The Royal Marsden and is Head of Clinical Oncology.

She is a Consultant Clinical Oncologist specialising in the treatment of gynaecological and skin cancers with radiotherapy, brachytherapy and systemic therapies. She qualified from the University of Southampton in 1998 and trained in oncology at The Royal Marsden and in South West Thames.

Dr Lalondrelle was awarded a clinical fellowship at The Institute of Cancer Research and completed research into the application of advanced radiotherapy technologies in pelvic tumours. Her research has been presented and published internationally and was awarded the Sylvia Lawler Prize from the Royal Society of Medicine.

Dr Lalondrelle is actively involved in clinical research leading a portfolio of trials in advanced radiotherapy techniques including MR guided radiotherapy, stereotactic radiotherapy, IGRT and adaptive planning and  image-guided brachytherapy in gynaecological cancers. Her research focuses on individualizing treatment delivery to minimise toxicity. She also has a strong interest in the combination of radiotherapy with novel systemic therapies including immunotherapy and the role of circulating HPV DNA in assessing response to treatment.

Dr Lalondrelle is the international lead for gynaecology in the MRlinac consortium and a member of the UK NCRI gynaecology and CTRad clinical study groups. 

 

Clinical units